139
Participants
Start Date
February 28, 2001
Study Completion Date
January 31, 2005
Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Sulbactam/Ampicillin
Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Berlin
Berlin
Treuenbrietzen
Lübeck
Rotenburg (Wümme)
Hildesheim
Paderborn
Magdeburg
Oberhausen
Lüdenscheid
Frankfurt am Main
Mannheim
Nuremberg
Regensburg
Leipzig
Lead Sponsor
Bayer
INDUSTRY